• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020
CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.PMID:36404170 | DOI:10.1016/j.vaccine.2022.11.003
Source: Vaccine - November 20, 2022 Category: Allergy & Immunology Authors: Keran Moll Bradley Lufkin Kathryn R Fingar Cindy Ke Zhou Ellen Tworkoski Chianti Shi Shayan Hobbi Mao Hu Minya Sheng Jillian McCarty Shanlai Shangguan Timothy Burrell Yoganand Chillarige Jeff Beers Patrick Saunders-Hastings Stella Muthuri Kathryn Edwards Source Type: research

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research

Examining Disparities and Excess Cardiovascular Mortality Before and During the COVID-19 Pandemic
To investigate the patterns and demographics of cardiovascular (CVD) death and subtypes myocardial infarction (MI), stroke, and heart failure (HF) in the pre-COVID-19 era (2018-2019) vs during COVID-19 pandemic (2020-2021) in the United States.
Source: Mayo Clinic Proceedings - July 20, 2022 Category: Internal Medicine Authors: Scott E. Janus, Mohamed Makhlouf, Nicole Chahine, Issam Motairek, Sadeer G. Al-Kindi Tags: Original Article Source Type: research

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021
CONCLUSION: Thrombosis with thrombocytopenia syndrome is a rare but serious adverse event associated with Ad26.COV2.S vaccination. The different demographic characteristics of the 3 cases reported after mRNA-based COVID-19 vaccines and the much lower reporting rate suggest that these cases represent a background rate.PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention.PMID:35038274 | DOI:10.7326/M21-4502
Source: Annals of Internal Medicine - January 17, 2022 Category: Internal Medicine Authors: Isaac See Allison Lale Paige Marquez Michael B Streiff Allison P Wheeler Naomi K Tepper Emily Jane Woo Karen R Broder Kathryn M Edwards Ruth Gallego Andrew I Geller Kelly A Jackson Shashi Sharma Kawsar R Talaat Emmanuel B Walter Imo J Akpan Thomas L Ortel Source Type: research

Challenges in managing ST elevation myocardial infarction during the COVID-19 pandemic
CONCLUSION: This single academic center study in the United States suggests that there is a delay in patients with STEMI seeking medical attention during the COVID-19 pandemic which could be translating into worse clinical outcomes.PMID:33968306 | PMC:PMC8069518 | DOI:10.4330/wjc.v13.i4.76
Source: World Journal of Cardiology - May 10, 2021 Category: Cardiology Authors: Megan Smith Aniruddha Singh Douglas McElroy Shilpi Mittal Richard Pham Source Type: research

Pages: 1  2  3  4